# Reduce Bolus Injection of Bivalirudin

Study · id `cardio:ct-nct03588611` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03588611](<https://clinicaltrials.gov/study/NCT03588611>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03588611

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 204 participants.

## Technical summary

Registry record NCT03588611. Randomized; double masking; primary purpose treatment. Start 2019-10-01 (actual); primary completion 2021-06-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 204 participants (enrolled count; ClinicalTrials.gov record NCT03588611, source copy `cardio:ctgov-nct03588611-2021-08-09`, retrieved 2026-10-31)
- Started: 2019-10-01 (actual) (ClinicalTrials.gov record NCT03588611, source copy `cardio:ctgov-nct03588611-2021-08-09`, retrieved 2026-10-31)
- Primary completion: 2021-06-26 (actual) (ClinicalTrials.gov record NCT03588611, source copy `cardio:ctgov-nct03588611-2021-08-09`, retrieved 2026-10-31)
- Completion: 2021-06-26 (actual) (ClinicalTrials.gov record NCT03588611, source copy `cardio:ctgov-nct03588611-2021-08-09`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT03588611, source copy `cardio:ctgov-nct03588611-2021-08-09`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03588611-2021-08-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: Reduce Bolus Injection of Bivalirudin
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Bivalirudin
- Intervention (Drug): Bivalirudin
- Lead sponsor: Han Yaling, MD
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry intervention name matches this record: Bivalirudin (`cardio:bivalirudin`)
- Registry intervention is a member of this class by a sourced record link: Anticoagulants (`cardio:anticoagulants`)

## Provenance

Content hash: 4ee65303389274dacb16b8fa20e6459d0567288f5347f29bda492e08ee05bf77
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
